CD274 and melanoma: In contrast, the bispecific anti-CD73/PDL1-HLE biologic significantly enhanced the control of tumor growth in the B16F10 melanoma model, or even led to complete tumor rejection in the EG7 model, as well as improved mice survival in both tumor models (Figures 5B, C and 6B, C).